Literature DB >> 14637196

Ecteinascidin-743 drug resistance in sarcoma cells: transcriptional and cellular alterations.

Li Shao1, Jeremy Kasanov, Francis J Hornicek, Takeshi Morii, Gertrude Fondren, Lawrence Weissbach.   

Abstract

A human chondrosarcoma cell line, CS-1, was treated successively with increasing concentrations of the marine chemotherapeutic Ecteinascidin-743 (ET-743), yielding a variant cell line displaying a significant degree of resistance to the cytotoxic action of this drug. Various experiments were performed to discern molecular aberrations between the parent and resistant cell line, and also identify potential molecular markers indicative of drug resistance. Although no significant differences in the levels of membrane transporters such as P-glycoprotein or multidrug resistance protein 1 (MRP1) were detected, the cell migratory ability of the ET-743-resistant cell variant was reduced, as was its attachment capability to gelatin-coated cell culture dishes. Staining of the actin-containing cytoskeleton with fluorescent-labeled phalloidin revealed marked differences in the cytoskeleton architecture between the parent and ET-743-resistant CS-1 cell lines. Comparison of serum-free conditioned medium from both cell lines showed conspicuous differences in the levels of several proteins, including a quartet of high molecular weight proteins (> or =140 kDa). The protein sequences of two of these high molecular weight proteins, present at significantly higher concentrations in conditioned medium obtained from the parent cell line, corresponded to subunits of types I and IV collagen. Analysis of type I collagen alpha1 chain mRNA revealed a significantly lower level in the ET-743-resistant CS-1 cell line. Thus, prolonged exposure to ET-743 may cause changes in cell function through cytoskeleton rearrangement and/or modulation of collagen levels.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14637196     DOI: 10.1016/j.bcp.2003.08.033

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

Review 1.  Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

Authors:  Natalie J Carter; Susan J Keam
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  HDAC4 represses vascular endothelial growth factor expression in chondrosarcoma by modulating RUNX2 activity.

Authors:  Xiaojuan Sun; Lei Wei; Qian Chen; Richard M Terek
Journal:  J Biol Chem       Date:  2009-06-09       Impact factor: 5.157

3.  Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma.

Authors:  Francois Lamoureux; Marc Baud'huin; Benjamin Ory; Romain Guiho; Amina Zoubeidi; Martin Gleave; Dominique Heymann; Françoise Rédini
Journal:  Oncotarget       Date:  2014-09-15

Review 4.  Intralesional curettage and cementation for low-grade chondrosarcoma of long bones: retrospective study and literature review.

Authors:  Musa Ugur Mermerkaya; Senol Bekmez; Fatih Karaaslan; Murat Danisman; Kemal Kosemehmetoglu; Gokhan Gedikoglu; Mehmet Ayvaz; Ahmet Mazhar Tokgozoglu
Journal:  World J Surg Oncol       Date:  2014-11-10       Impact factor: 2.754

5.  Wnt inhibitory factor 1 (WIF1) methylation and its association with clinical prognosis in patients with chondrosarcoma.

Authors:  Pei Liu; Jacson K Shen; Francis J Hornicek; Fuyun Liu; Zhenfeng Duan
Journal:  Sci Rep       Date:  2017-05-08       Impact factor: 4.379

6.  Establishment and Characterization of a Novel Dedifferentiated Chondrosarcoma Cell Line DDCS2.

Authors:  Xiaoyang Li; Dylan C Dean; Al Ferreira; Scott D Nelson; Francis J Hornicek; Shengji Yu; Zhenfeng Duan
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

7.  ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.

Authors:  Zhenfeng Duan; Edwin Choy; David Harmon; Cao Yang; Keinosuke Ryu; Joseph Schwab; Henry Mankin; Francis J Hornicek
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

8.  Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.

Authors:  B Colmegna; S Uboldi; R Frapolli; S A Licandro; N Panini; C M Galmarini; Nadia Badri; V J Spanswick; J P Bingham; Konstantinos Kiakos; E Erba; J A Hartley; M D'Incalci
Journal:  Br J Cancer       Date:  2015-12-03       Impact factor: 7.640

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.